SHARE

TrovaGene Inc (NASDAQ:TROV) reported the strengthening and expansion of its Board with the election of Athena Countouriotis, M.D., who brings extensive experience leading clinical advancement programs, from preclinical through clinical phases, and approval. During the course of her career, Dr. Countouriotis has been involved in numerous clinical plans, with a focus within oncology that have supported regulatory nods in the United States and Europe.

The details

Dr. Countouriotis currently is the SVP, CMO at Adverum Biotechnologies. Before joining Adverum, she was the Chief Medical Officer and Senior Vice President at Halozyme Therapeutics. Dr. Countouriotis served as CMO at Ambit Biosciences through the preliminary advancement of quizartinib and ultimate acquisition of the firm by Daiichi Sankyo.

She also worked at both Bristol-Myers Squibb Co (NYSE:BMY) and Pfizer Inc.(NYSE:PFE) in numerous roles leading clinical development of oncology focused therapeutics. Bill Welch, the CEO of Trovagene, expressed that they are delighted to welcome Dr. Countouriotis to their Board of Directors. Dr. Countouriotis has remarkable expertise in the clinical advancement of oncology therapeutics, including numerous compounds in leukemia like Mylotarg, Bosulif, Quizartinib and Sprycel. They look forward to her guidance and contributions as they continue to develop PCM-075 for the treatment of people with solid tumor cancers and hematologic.

Commenting on her new role, Dr. Countouriotis expressed that it is a thrilling time at company as they embark on advancing PCM-075 into the clinic in AML. It marks as a great time to join TrovaGene Board and share her expertise with the firm, and she look forward to be associating with the Trovagene team.

PCM-075 marks as a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK 1 enzyme, which is over-expressed in numerous solid tumor cancers and hematologic. Studies have demonstrated that inhibition of PLK1 can result in tumor cell death, including numerous Phase 2 trials in Acute Myeloid Leukemia where response rates of up to 30% were noted.

TrovaGene intends to start a Phase 1b/2 clinical study with PCM-075 in AML, since it has demonstrated considerable advantages over previous PLK1 inhibitors assessed in this indication, including a greater potency, higher selectivity, shorter half-life and oral bioavailability.

LEAVE A REPLY